journal article·2022-10-28

Zeolitic Imidazolate Framework Nanoencapsulation of CpG for Stabilization and Enhancement of Immunoadjuvancy

Olivia R. Brohlin, Ryanne N. Ehrman, Fabian C. Herbert, Yalini H. Wijesundara, Arun Raja, Arezoo Shahrivarkevishahi, Shashini D. Diwakara, Ronald A. Smaldone, Jeremiah J. Gassensmith

ACS Applied Nano Materials· Volume 5· Issue 10
Publisher page

Abstract

Metal–organic frameworks (MOFs) have been used to improve vaccine formulations by stabilizing proteins and protecting them against thermal degradation. This has led to increased immunogenicity of these proteinaceous therapeutics. In this work, we show that MOFs can also be used to protect the single-stranded DNA oligomer CpG to increase its immunoadjuvancy. By encapsulation of the phosphodiester CpG in the zinc-based MOF, zeolitic imidazolate framework-8, the DNA oligomer is protected from nuclease degradation and exhibits improved cellular uptake. As a result, we have been able to achieve drastically enhanced B-cell activation in splenocyte cultures comparable to the current state-of-the-art phosphorothioate CpG. Furthermore, we have made a direct comparison of micro- and nanosized MOFs for optimization of the particulate delivery of immunoadjuvants to maximize immune activation.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry and Biochemistry, The University of Texas at Dallas, 800 West Campbell Road, Richardson, Texas 75080, United States

Department of Biomedical Engineering, The University of Texas at Dallas, 800 West Campbell Road, Richardson, Texas 75080, United States

Funding

Welch Foundation · Division of Materials Research

References (68)

Show source-provided references
1. 10.1021/jacs.8b1030210.1021/jacs.8b10302 ↗
2. 10.1002/adhm.20180095010.1002/adhm.201800950 ↗
3. 10.1021/acsami.8b2050410.1021/acsami.8b20504 ↗
4. 10.1038/s41467-021-22285-y10.1038/s41467-021-22285-y ↗
5. 10.1021/acs.bioconjchem.8b0048310.1021/acs.bioconjchem.8b00483 ↗
6. 10.1002/wnan.173510.1002/wnan.1735 ↗
7. 10.1021/cr300014x10.1021/cr300014x ↗
8. 10.1039/C4CS90059F10.1039/C4CS90059F ↗
9. 10.1039/b903811f10.1039/b903811f ↗
10. 10.1039/C8SC03987A10.1039/C8SC03987A ↗
11. 10.1021/acsbiomaterials.0c0093510.1021/acsbiomaterials.0c00935 ↗
12. 10.1021/nl502641910.1021/nl5026419 ↗
13. 10.1038/ncomms824010.1038/ncomms8240 ↗
14. 10.1021/jacs.8b0208910.1021/jacs.8b02089 ↗
15. 10.1021/acsami.9b2352610.1021/acsami.9b23526 ↗
16. 10.1021/acsami.1c0070610.1021/acsami.1c00706 ↗
17. 10.1016/j.ccr.2020.21338810.1016/j.ccr.2020.213388 ↗
18. 10.1021/acsomega.0c0118910.1021/acsomega.0c01189 ↗
19. 10.1073/pnas.060243910310.1073/pnas.0602439103 ↗
20. 10.1002/anie.20160487910.1002/anie.201604879 ↗
21. Li S. · 2018 · 1798 · 95
22. 10.1186/s12951-020-00694-310.1186/s12951-020-00694-3 ↗
23. 10.2217/nnm-2018-034710.2217/nnm-2018-0347 ↗
24. 10.1080/10610278.2019.161608910.1080/10610278.2019.1616089 ↗
25. Florindo H. F. · 2017 · 39310.1016/B978-0-323-39981-4.00021-X ↗
26. 10.3390/vaccines801012810.3390/vaccines8010128 ↗
27. 10.3390/pharmaceutics1305064410.3390/pharmaceutics13050644 ↗
28. 10.1016/B978-0-323-68299-2.00016-210.1016/B978-0-323-68299-2.00016-2 ↗
29. 10.1038/s41573-021-00163-y10.1038/s41573-021-00163-y ↗
30. 10.1038/374546a010.1038/374546a0 ↗
31. 10.2174/138920372066619083016214910.2174/1389203720666190830162149 ↗
32. 10.1002/ijc.2140210.1002/ijc.21402 ↗
33. 10.1016/j.gene.2004.02.04310.1016/j.gene.2004.02.043 ↗
34. 10.1586/erv.10.17410.1586/erv.10.174 ↗
35. 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U ↗
36. 10.4049/jimmunol.164.3.161710.4049/jimmunol.164.3.1617 ↗
37. 10.1016/j.vaccine.2010.08.00210.1016/j.vaccine.2010.08.002 ↗
38. Shirota H. · 2017 · 16310.1016/B978-0-12-804019-5.00009-8 ↗
39. van den Boorn J. G. · 2012 · 114 · 1
40. 10.1111/j.1365-2222.2008.03191.x10.1111/j.1365-2222.2008.03191.x ↗
41. 10.1016/j.jconrel.2004.02.02210.1016/j.jconrel.2004.02.022 ↗
42. 10.3390/cells909206110.3390/cells9092061 ↗
43. 10.1038/s41598-017-15178-y10.1038/s41598-017-15178-y ↗
44. 10.1002/adfm.20160065010.1002/adfm.201600650 ↗
45. 10.1002/smll.20190226810.1002/smll.201902268 ↗
46. 10.1021/acsnano.1c0309210.1021/acsnano.1c03092 ↗
47. 10.1021/acsami.9b1566710.1021/acsami.9b15667 ↗
48. 10.1038/s41578-021-00358-010.1038/s41578-021-00358-0 ↗
49. 10.1080/14760584.2018.151655210.1080/14760584.2018.1516552 ↗
50. 10.2147/IJN.S2676610.2147/IJN.S26766 ↗
51. 10.1021/jacs.8b0445710.1021/jacs.8b04457 ↗
52. 10.1021/acsami.7b0958310.1021/acsami.7b09583 ↗
53. 10.1016/j.addr.2016.05.02010.1016/j.addr.2016.05.020 ↗
54. 10.1080/21645515.2015.111771410.1080/21645515.2015.1117714 ↗
55. 10.1039/D0CS01127D10.1039/D0CS01127D ↗
56. 10.1126/science.115206610.1126/science.1152066 ↗
57. 10.3389/fimmu.2017.0151310.3389/fimmu.2017.01513 ↗
58. 10.1021/acsami.8b0136910.1021/acsami.8b01369 ↗
59. 10.3389/fbioe.2020.0071410.3389/fbioe.2020.00714 ↗
60. 10.1039/C9CC09358C10.1039/C9CC09358C ↗
61. 10.1002/adma.20160233510.1002/adma.201602335 ↗
62. 10.1007/s40843-018-9384-810.1007/s40843-018-9384-8 ↗
63. 10.1002/adhm.20200004610.1002/adhm.202000046 ↗
64. 10.3390/ijms2102051010.3390/ijms21020510 ↗
65. 10.1002/bip.2068910.1002/bip.20689 ↗
66. 10.1039/c2dt30357d10.1039/c2dt30357d ↗
67. 10.1038/s41401-020-0414-610.1038/s41401-020-0414-6 ↗
68. 10.1016/j.micromeso.2020.11017310.1016/j.micromeso.2020.110173 ↗